

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Currently amended) A method of reducing treating and ameliorating endotoxin-mediated induced cytokine production in a human patient suffering from cachexia or body wasting in a human patient with liver cirrhosis, the method comprising administering to the human patient ~~an~~ a therapeutically effective amount of ursodeoxycholic acid, a compound that is able to reduce the production, absorption and/or the effect of an endotoxin (lipopolysaccharide).

2. (Cancelled)

3. (Currently amended) A method according to claim 1 wherein the ~~compound~~ ursodeoxycholic acid is able to bind to an endotoxin (lipopolysaccharide) molecule.

4. (Currently amended) A method according to claim 1 wherein the ~~compound~~ ursodeoxycholic acid is able to reduce the available endotoxin in the patient.

5. (Cancelled)

6. (Cancelled)

7. (Canceled)

8. (Canceled)

9. (Canceled)

10. (Canceled)

11. (Canceled)

12. (Canceled)

13. (Canceled)

14. (Canceled)

15. (Canceled)

16. (Canceled)

17. (Canceled)

18. (Canceled)

19. (Canceled)

20. (Currently amended) A method according to claim 1 wherein the compound ursodeoxycholic acid is administered orally.

21. (Currently amended) A method according to claim 1 wherein the compound ursodeoxycholic acid is administered intravenously.

22. (Currently amended) A method according to claim 1 wherein the compound ursodeoxycholic acid is administered rectally.

23. (Canceled)

24. (New) The method according to claim 1 wherein cachexia is due to renal failure, heart failure, rheumatoid arthritis, chronic obstructive pulmonary disease, or diabetes.